Johnson & Johnson Reports Q2 2023 Results

  • 2023 Second-Quarter reported sales growth of 6.3% to $25.5 Billion with operational growth of 7.5%* and adjusted operational growth of 6.2%*. Operational growth excluding COVID-19 Vaccine of 8.9%*
  • Earnings per share (EPS) of $1.96 increasing 8.9% and adjusted EPS of $2.80 increasing by 8.1%*
  • Company is increasing 2023 full-year guidance midpoints for adjusted operational sales excluding COVID-19 Vaccine and adjusted operational EPS
  • Johnson & Johnson intends to "split off" Kenvue shares through an exchange offer as the form of its next step in the separation, subject to market conditions

NEW BRUNSWICK, N.J.--()--Johnson & Johnson (NYSE: JNJ) today announced results for second-quarter 2023. “Our robust performance in the second quarter and first half of 2023 is a testament to the hard work and commitment of our colleagues around the world,” said Joaquin Duato, Chairman of the Board and Chief Executive Officer. “We are entering the back half of the year from a position of strength with numerous catalysts, including becoming a two-sector company focused on Pharmaceutical and MedTech innovation.”

OVERALL FINANCIAL RESULTS

Q2

($ in Millions, except EPS)

2023

2022

% Change

Reported Sales

$25,530

$24,020

6.3%

Net Earnings/(Loss)

$5,144

$4,814

6.9%

EPS (diluted)

$1.96

$1.80

8.9%

 

Q2

Non-GAAP* ($ in Millions, except EPS)

2023

2022

% Change

Operational Sales1,2

7.5%

Adjusted Operational Sales1,3

6.2%

Adjusted Net Earnings1,4

$7,358

$6,912

6.5%

Adjusted EPS (diluted)1,4

$2.80

$2.59

8.1%

1

Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules

2

Excludes the impact of translational currency

3

Excludes the net impact of acquisitions and divestitures and translational currency

4

Excludes intangible amortization expense and special items

Note: Values may have been rounded

REGIONAL SALES RESULTS

Q2

% Change

($ in Millions)

2023

2022

Reported

Operational1,2

Currency

Adjusted Operational1,3

U.S.

$13,444

$12,197

10.2%

10.2

-

8.0

International

12,086

11,823

2.2

4.7

(2.5)

4.4

Worldwide

$25,530

$24,020

6.3%

7.5

(1.2)

6.2

1

Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules

2

Excludes the impact of translational currency

3

Excludes the net impact of acquisitions and divestitures and translational currency

Note: Values may have been rounded

SEGMENT SALES RESULTS

Q2

 

 

% Change

($ in Millions)

2023

2022

Reported

Operational1,2

Currency

Adjusted Operational1,3

Consumer Health

$4,011

$3,805

5.4%

7.7

(2.3)

7.7

Pharmaceutical

13,731

13,317

3.1

3.8

(0.7)

3.9

MedTech

7,788

6,898

12.9

14.7

(1.8)

9.9

Worldwide

$25,530

$24,020

6.3%

7.5

(1.2)

6.2

1

Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules

2

Excludes the impact of translational currency

3

Excludes the net impact of acquisitions and divestitures and translational currency

Note: Values may have been rounded

SECOND QUARTER 2023 SEGMENT COMMENTARY:
Adjusted operational sales* reflected below excludes the net impact of acquisitions and divestitures and translational currency.

Pharmaceutical
Pharmaceutical worldwide adjusted operational sales grew 3.9%*. Excluding the COVID-19 Vaccine, adjusted operational sales grew 6.2%*. Growth was driven by DARZALEX (daratumumab), ERLEADA (apalutamide), and CARVYKTI (ciltacabtagene autoleucel) in Oncology, STELARA (ustekinumab) and TREMFYA (guselkumab) in Immunology, UPTRAVI (selexipag) and OPSUMIT (macitentan) in Pulmonary Hypertension, and SPRAVATO (esketamine) in Neuroscience. Growth was partially offset by ZYTIGA (abiraterone acetate) and IMBRUVICA (ibrutinib) in Oncology, COVID-19 Vaccine (Ad26.COV2.S) in Infectious Diseases, and REMICADE (infliximab) in Immunology.

MedTech
MedTech worldwide adjusted operational sales grew 9.9%*, driven primarily by electrophysiology products in Interventional Solutions, trauma in Orthopaedics, wound closure products in General Surgery, biosurgery in Advanced Surgery, and contact lenses in Vision. MedTech worldwide operational sales grew 14.7%*, with the acquisition of Abiomed contributing 4.8%.

Consumer Health
Consumer Health worldwide adjusted operational sales increased 7.7%* largely driven by over-the-counter (OTC) products. Major contributors to growth in OTC were TYLENOL and MOTRIN analgesics, upper respiratory products, international smoking cessation products, and IMODIUM in digestive health products. Additional contributors to growth were NEUTROGENA in Skin Health/Beauty products and Women’s Health products outside the United States.

NOTABLE NEW ANNOUNCEMENTS IN THE QUARTER:
The information contained in this section should be read in conjunction with Johnson & Johnson’s other disclosures filed with the Securities and Exchange Commission, including its Current Reports on Form 8-K, Quarterly Reports on Form 10-Q and Annual Reports on Form 10-K. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. The reader is also encouraged to review all other news releases and information available in the Investors section of the company’s website at news releases, as well as www.factsabouttalc.com, www.factsaboutourprescriptionopioids.com, and www.LTLManagementInformation.com.

Regulatory

Janssen Marks First Approval Worldwide for AKEEGA (Niraparib and Abiraterone Acetate Dual Action Tablet) with EC Authorisation for the Treatment of Patients with Metastatic Castration Resistant Prostate Cancer with BRCA1/2 Mutations

Press Release

Milvexian Granted U.S. FDA Fast Track Designation for All Three Indications Under Evaluation in Phase 3 Librexia Program: Ischemic Stroke, Acute Coronary Syndrome and Atrial Fibrillation

Press Release

Janssen Submits New Drug Application to U.S. FDA Seeking Approval of Investigational Single Tablet Combination Therapy of Macitentan and Tadalafil for Treatment of Patients with Pulmonary Arterial Hypertension (PAH)

Press Release

Janssen Submits Supplemental Biologics License Application to U.S. FDA Seeking Approval of CARVYKTI for the Earlier Treatment of Patients with Relapsed or Refractory Multiple Myeloma

Press Release

Data Release

Janssen Reports First Results from Phase 2 SunRISe-1 Study of TAR-200 and Anti-PD-1 Antibody Cetrelimab in Patients with Bacillus Calmette-Guérin-Unresponsive Non-Muscle-Invasive Bladder Cancer

Press Release

First Phase 3 TREMFYA (guselkumab) Data in Inflammatory Bowel Disease Show Positive Induction Results Among Patients with Moderately to Severely Active Ulcerative Colitis

Press Release

New Data Published on Biosense Webster QDOT MICRO Catheter – the Latest Advancement in Focal RF Ablation for Treating AFib

Press Release

Janssen to Highlight Scientific Advances and Commitment to Transform Cancer Care at ASCO and EHA with More than 90 Presentations Showcasing Robust, Differentiated Portfolio and Pipeline in Hematologic Malignancies and Solid Tumors

Press Release

New Phase 2 Data Demonstrate Potential Benefit of Nipocalimab for Pregnant Individuals at High Risk of Early-Onset Severe Hemolytic Disease of the Fetus and Newborn (HDFN)

Press Release

Janssen Announces Positive Topline Results for JNJ-2113—a Novel, First and Only Oral IL-23 Receptor Antagonist Peptide in Development for Moderate-to-Severe Plaque Psoriasis1

Press Release

Treatment with RYBREVANT (amivantamab-vmjw) Plus Chemotherapy Resulted in Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival in Patients with Newly Diagnosed EGFR Exon 20 Insertion Mutation-Positive Non-Small Cell Lung Cancer1

Press Release

 

Other

Johnson & Johnson Announces Launch of Kenvue Inc. IPO Roadshow

Press Release

Janssen Enters Worldwide Collaboration and License Agreement with Cellular Biomedicine Group to Develop Next Generation CAR-T Therapies

Press Release

1

Subsequent to the quarter

FULL-YEAR 2023 GUIDANCE:
Johnson & Johnson does not provide GAAP financial measures on a forward-looking basis because the company is unable to predict with reasonable certainty the ultimate outcome of legal proceedings, unusual gains and losses, acquisition-related expenses and purchase accounting fair value adjustments without unreasonable effort. These items are uncertain, depend on various factors, and could be material to Johnson & Johnson's results computed in accordance with GAAP.

($ in Billions, except EPS)

July 2023

April 2023

Adjusted Operational Sales1,2,5

Change vs. Prior Year / Mid-point

6.0% – 7.0% / 6.5%

4.5% – 5.5% / 5.0%

Operational Sales2,5/ Mid-point

Change vs. Prior Year / Mid-point

$99.3B – $100.3B / $99.8B
7.0% – 8.0% / 7.5%

$97.9B – $98.9B / $98.4B
5.5% – 6.5% / 6.0%

Estimated Reported Sales3,5/ Mid-point

Change vs. Prior Year / Mid-point

$98.8B – $99.8B / $99.3B
6.5% – 7.5% / 7.0%

$97.9B – $98.9B / $98.4B
5.5% – 6.5% / 6.0%

 

 

 

Adjusted Operational EPS (Diluted)2,4/ Mid-point

Change vs. Prior Year / Mid-point

$10.60 – $10.70 / $10.65
4.5% – 5.5% / 5.0%

$10.50 – $10.60 / $10.55
3.5% – 4.5% / 4.0%

Adjusted EPS (Diluted)3,4 / Mid-point

Change vs. Prior Year / Mid-point

$10.70 – $10.80 / $10.75
5.5% – 6.5% / 6.0%

$10.60 – $10.70 / $10.65
4.5% – 5.5% / 5.0%

1

Non-GAAP financial measure; excludes the net impact of acquisitions and divestitures

2

Non-GAAP financial measure; excludes the impact of translational currency

3

Calculated using Euro Average Rate: July 2023 = $1.09 and April 2023 = $1.10 (Illustrative purposes only)

4

Non-GAAP financial measure; excludes intangible amortization expense and special items

5

Excludes COVID-19 Vaccine

Note: percentages may have been rounded

Other modeling considerations will be provided on the webcast.

WEBCAST INFORMATION:
Johnson & Johnson will conduct a conference call with investors to discuss this earnings release today at 8:30 a.m., Eastern Time. A simultaneous webcast of the call for investors and other interested parties may be accessed by visiting the Johnson & Johnson website. A replay and podcast will be available approximately two hours after the live webcast in the Investors section of the company's website at events-and-presentations.

ABOUT JOHNSON & JOHNSON:
At Johnson & Johnson, we believe good health is the foundation of vibrant lives, thriving communities and forward progress. That’s why for more than 135 years, we have aimed to keep people well at every age and every stage of life. Today, as the world’s largest, most diversified healthcare products company, we are committed to using our reach and size for good. We strive to improve access and affordability, create healthier communities, and put a healthy mind, body and environment within reach of everyone, everywhere. We are blending our heart, science and ingenuity to profoundly change the trajectory of health for humanity.

NON-GAAP FINANCIAL MEASURES:
* “Operational sales growth” excluding the impact of translational currency, “adjusted operational sales growth” excluding the net impact of acquisitions and divestitures and translational currency, as well as “adjusted net earnings”, “adjusted diluted earnings per share” and “adjusted operational diluted earnings per share” excluding after-tax intangible amortization expense and special items, are non-GAAP financial measures and should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures. Except for guidance measures, reconciliations of these non-GAAP financial measures to the most directly comparable GAAP financial measures can be found in the accompanying financial schedules of the earnings release and the Investors section of the company's website at quarterly results.

Copies of the financial schedules accompanying this earnings release are available on the company’s website at quarterly results. These schedules include supplementary sales data, a condensed consolidated statement of earnings, reconciliations of non-GAAP financial measures, and sales of key products/franchises. Additional information on Johnson & Johnson, including adjusted income before tax by segment, a pharmaceutical pipeline of selected compounds in late stage development and a copy of today’s earnings call presentation can also be found in the Investors section of the company's website at quarterly results.

NOTE TO INVESTORS CONCERNING FORWARD-LOOKING STATEMENTS:
This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things: future operating and financial performance, product development, market position and business strategy, and the anticipated separation of the Company’s Consumer Health business. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: economic factors, such as interest rate and currency exchange rate fluctuations; competition, including technological advances, new products and patents attained by competitors; challenges inherent in new product research and development, including uncertainty of clinical success and obtaining regulatory approvals; uncertainty of commercial success for new and existing products; challenges to patents; the impact of patent expirations; the ability of the company to successfully execute strategic plans, including restructuring plans; the impact of business combinations and divestitures; manufacturing difficulties or delays, internally or within the supply chain; product efficacy or safety concerns resulting in product recalls or regulatory action; significant adverse litigation or government action, including related to product liability claims; changes to applicable laws and regulations, including tax laws and global health care reforms; trends toward health care cost containment; changes in behavior and spending patterns of purchasers of health care products and services; financial instability of international economies and legal systems and sovereign risk; increased scrutiny of the health care industry by government agencies; the Company’s ability to satisfy the necessary conditions to consummate the separation of the Company’s Consumer Health business on a timely basis or at all; the Company’s ability to successfully separate the Company’s Consumer Health business and realize the anticipated benefits from the separation; and the New Consumer Health Company’s ability to succeed as a standalone publicly traded company. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson’s Annual Report on Form 10-K for the fiscal year ended January 1, 2023, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in Johnson & Johnson’s subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. Any forward-looking statement made in this release speaks only as of the date of this release. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.

Johnson & Johnson and Subsidiaries

Supplementary Sales Data
 
(Unaudited; Dollars in Millions)

SECOND QUARTER

SIX MONTHS

 

 

 

 

Percent Change

 

 

 

 

Percent Change

2023

2022

Total

Operations

Currency

2023

2022

Total

Operations

Currency

Sales to customers by
segment of business
 
Consumer Health
U.S.

$

1,787

1,687

6.0

 

%

6.0

 

-

 

$

3,522

3,244

8.6

 

%

8.6

-

 

International

 

2,224

2,118

5.0

 

9.0

 

(4.0

)

 

4,341

4,147

4.7

 

10.1

(5.4

)

 

4,011

3,805

5.4

 

7.7

 

(2.3

)

 

7,863

7,391

6.4

 

9.5

(3.1

)

 
Pharmaceutical (1)
U.S.

 

7,818

7,159

9.2

 

9.2

 

-

 

 

14,841

13,791

7.6

 

7.6

-

 

International

 

5,913

6,158

(4.0

)

(2.5

)

(1.5

)

 

12,303

12,395

(0.7

)

3.1

(3.8

)

 

13,731

13,317

3.1

 

3.8

 

(0.7

)

 

27,144

26,186

3.7

 

5.5

(1.8

)

 
Pharmaceutical excluding COVID-19 Vaccine (1)
U.S.

 

7,818

7,114

9.9

 

9.9

 

-

 

 

14,841

13,671

8.6

 

8.6

-

 

International

 

5,628

5,659

(0.5

)

1.5

 

(2.0

)

 

11,271

11,514

(2.1

)

1.9

(4.0

)

 

13,446

12,773

5.3

 

6.2

 

(0.9

)

 

26,112

25,185

3.7

 

5.5

(1.8

)

 
MedTech (1)
U.S.

 

3,839

3,351

14.6

 

14.6

 

-

 

 

7,598

6,576

15.5

 

15.5

-

 

International

 

3,949

3,547

11.3

 

14.7

 

(3.4

)

 

7,671

7,293

5.2

 

10.3

(5.1

)

 

7,788

6,898

12.9

 

14.7

 

(1.8

)

 

15,269

13,869

10.1

 

12.8

(2.7

)

 
U.S.

 

13,444

12,197

10.2

 

10.2

 

-

 

 

25,961

23,611

10.0

 

10.0

-

 

International

 

12,086

11,823

2.2

 

4.7

 

(2.5

)

 

24,315

23,835

2.0

 

6.5

(4.5

)

Worldwide

 

25,530

24,020

6.3

 

7.5

 

(1.2

)

 

50,276

47,446

6.0

 

8.2

(2.2

)

 
U.S.

 

13,444

12,152

10.6

 

10.6

 

-

 

 

25,961

23,491

10.5

 

10.5

-

 

International

 

11,801

11,324

4.2

 

7.0

 

(2.8

)

 

23,283

22,954

1.4

 

6.1

(4.7

)

Worldwide excluding COVID-19 Vaccine (1)

$

25,245

23,476

7.5

 

%

8.9

 

(1.4

)

$

49,244

46,445

6.0

 

%

8.3

(2.3

)

Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.
(1) Refer to supplemental sales reconciliation schedule
Johnson & Johnson and Subsidiaries
Supplementary Sales Data
 
(Unaudited; Dollars in Millions)

SECOND QUARTER

SIX MONTHS

Percent Change

Percent Change

2023

2022

Total

Operations

Currency

2023

2022

Total

Operations

Currency

Sales to customers by
geographic area
 
U.S.

$

13,444

12,197

10.2

 

%

10.2

 

-

 

$

25,961

23,611

10.0

%

10.0

-

 

 
Europe

 

5,894

6,085

(3.1

)

(3.9

)

0.8

 

 

12,226

12,109

1.0

3.0

(2.0

)

Western Hemisphere excluding U.S.

 

1,713

1,536

11.5

 

17.7

 

(6.2

)

 

3,300

3,018

9.3

16.1

(6.8

)

Asia-Pacific, Africa

 

4,479

4,202

6.6

 

12.5

 

(5.9

)

 

8,789

8,708

0.9

8.2

(7.3

)

International

 

12,086

11,823

2.2

 

4.7

 

(2.5

)

 

24,315

23,835

2.0

6.5

(4.5

)

 
Worldwide

$

25,530

24,020

6.3

 

%

7.5

 

(1.2

)

$

50,276

47,446

6.0

%

8.2

(2.2

)

 

Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.

Johnson & Johnson and Subsidiaries
Condensed Consolidated Statement of Earnings
 
(Unaudited; in Millions Except Per Share Figures)

SECOND QUARTER

 

2023

2022

Percent

Percent

Percent

Increase

Amount

to Sales

Amount

to Sales

(Decrease)

Sales to customers

$

25,530

 

100.0

 

$

24,020

 

100.0

 

6.3

Cost of products sold

 

8,212

 

32.2

 

 

7,919

 

33.0

 

3.7

Gross Profit

 

17,318

 

67.8

 

 

16,101

 

67.0

 

7.6

Selling, marketing and administrative expenses

 

6,665

 

26.1

 

 

6,226

 

25.9

 

7.1

Research and development expense

 

3,829

 

15.0

 

 

3,703

 

15.4

 

3.4

Interest (income) expense, net

 

(23

)

(0.1

)

 

(26

)

(0.1

)

Other (income) expense, net*

 

(60

)

(0.2

)

 

273

 

1.1

 

Restructuring

 

145

 

0.5

 

 

85

 

0.4

 

Earnings before provision for taxes on income

 

6,762

 

26.5

 

 

5,840

 

24.3

 

15.8

Provision for taxes on income

 

1,618

 

6.4

 

 

1,026

 

4.3

 

57.7

Net earnings

$

5,144

 

20.1

 

$

4,814

 

20.0

 

6.9

 
Net earnings per share (Diluted)

$

1.96

 

$

1.80

 

8.9

 
Average shares outstanding (Diluted)

 

2,625.7

 

 

2,667.9

 

 
Effective tax rate

 

23.9

 

%

 

17.6

 

%

 
Adjusted earnings before provision for taxes and net earnings (1)
Earnings before provision for taxes on income

$

8,824

 

34.6

 

$

8,171

 

34.0

 

8.0

Net earnings

$

7,358

 

28.8

 

$

6,912

 

28.8

 

6.5

Net earnings per share (Diluted)

$

2.80

 

$

2.59

 

8.1

Effective tax rate

 

16.6

 

%

 

15.4

 

%

* Fiscal second quarter Other (income) expense, net includes $37 million related to the Company's 10.4% non-controlling interest in Kenvue, Inc. from the time of the initial public offering on May 8, 2023 through the end of the fiscal second quarter.
(1) See Reconciliation of Non-GAAP Financial Measures.
Johnson & Johnson and Subsidiaries
Condensed Consolidated Statement of Earnings
 
(Unaudited; in Millions Except Per Share Figures)

SIX MONTHS

 

2023

2022

Percent

 

Percent

 

Percent

 

Increase

 

Amount

 

to Sales

 

Amount

 

to Sales

 

(Decrease)

 

Sales to customers

$

50,276

 

100.0

 

$

47,446

 

100.0

 

6.0

 

Cost of products sold

 

16,607

 

33.0

 

 

15,517

 

32.7

 

7.0

 

Gross Profit

 

33,669

 

67.0

 

 

31,929

 

67.3

 

5.4

 

Selling, marketing and administrative expenses

 

12,803

 

25.5

 

 

12,164

 

25.6

 

5.3

 

Research and development expense

 

7,392

 

14.7

 

 

7,165

 

15.1

 

3.2

 

In-process research and development

 

49

 

0.1

 

 

610

 

1.3

 

Interest (income) expense, net

 

(43

)

(0.1

)

 

(38

)

(0.1

)

Other (income) expense, net*

 

7,168

 

14.3

 

 

171

 

0.4

 

Restructuring

 

275

 

0.5

 

 

155

 

0.3

 

Earnings before provision for taxes on income

 

6,025

 

12.0

 

 

11,702

 

24.7

 

(48.5

)

Provision for taxes on income

 

949

 

1.9

 

 

1,739

 

3.7

 

(45.4

)

Net earnings

$

5,076

 

10.1

 

$

9,963

 

21.0

 

(49.1

)

 
Net earnings per share (Diluted)

$

1.93

 

$

3.73

 

(48.3

)

 
Average shares outstanding (Diluted)

 

2,630.7

 

 

2,669.2

 

 
Effective tax rate

 

15.8

 

%

 

14.9

 

%

 
Adjusted earnings before provision for taxes and net earnings (1)
Earnings before provision for taxes on income

$

17,292

 

34.4

 

$

16,389

 

34.5

 

5.5

 

Net earnings

$

14,426

 

28.7

 

$

14,041

 

29.6

 

2.7

 

Net earnings per share (Diluted)

$

5.48

 

$

5.26

 

4.2

 

Effective tax rate

 

16.6

 

%

 

14.3

 

%

* Fiscal six months Other (income) expense, net includes $37 million related to the Company's 10.4% non-controlling interest in Kenvue, Inc. from the time of the initial public offering on May 8, 2023 through the end of the fiscal second quarter.
(1) See Reconciliation of Non-GAAP Financial Measures.
 
Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measures
 

Second Quarter

Six Months Ended

(Dollars in Millions Except Per Share Data)

 

2023

 

 

2022

 

 

2023

 

 

2022

 

Net Earnings, after tax- as reported

$

5,144

 

$

4,814

 

$

5,076

 

$

9,963

 

 
Pre-tax Adjustments
Litigation related

 

137

 

 

385

 

 

7,037

 

 

385

 

Intangible Asset Amortization expense

 

1,211

 

 

1,095

 

 

2,415

 

 

2,203

 

COVID-19 Vaccine related costs 1

 

165

 

 

276

 

 

609

 

 

276

 

Consumer Health separation costs

 

282

 

 

268

 

 

582

 

 

370

 

Restructuring related 2

 

145

 

 

128

 

 

275

 

 

200

 

Medical Device Regulation 3

 

85

 

 

70

 

 

149

 

 

130

 

Acquisition, integration and divestiture related

 

38

 

 

-

 

 

80

 

 

-

 

(Gains)/losses on securities

 

(1

)

 

109

 

 

71

 

 

520

 

IPR&D

 

-

 

 

-

 

 

49

 

 

610

 

Other

 

-

 

 

-

 

 

-

 

 

(7

)

 
Tax Adjustments
Tax impact on special item adjustments 4

 

(373

)

 

(313

)

 

(2,430

)

 

(706

)

Consumer Health separation tax related costs

 

546

 

 

2

 

 

557

 

 

98

 

Tax legislation and other tax related

 

(21

)

 

78

 

 

(44

)

 

(1

)

Adjusted Net Earnings, after tax

$

7,358

 

$

6,912

 

$

14,426

 

$

14,041

 

Average shares outstanding (Diluted)

 

2,625.7

 

 

2,667.9

 

 

2,630.7

 

 

2,669.2

 

Adjusted net earnings per share (Diluted)

$

2.80

 

$

2.59

 

$

5.48

 

$

5.26

 

Operational adjusted net earnings per share (Diluted)

$

2.84

 

$

5.59

 

 
Notes:

1

COVID-19 Vaccine related costs include remaining commitments and obligations, including external manufacturing network exit costs and required clinical trial expenses, associated with the Company's completion of its COVID-19 vaccine contractual commitments.

 

2

 

In the first and second quarter of 2023, the company completed a prioritization of its research and development (R&D) investment within the Pharmaceutical segment to focus on the most promising medicines with the greatest benefit to patients. This resulted in the exit of certain programs within therapeutic areas. The R&D program exits are primarily in infectious diseases and vaccines including the discontinuation of its respiratory syncytial virus (RSV) adult vaccine program, hepatitis and HIV development. The restructuring expenses of $145 million in the quarter ($275 million Q2 YTD) include the termination of partnered and non-partnered program costs and asset impairments.

 

3

 

European Medical Device Regulation (MDR) costs represent one-time compliance costs for the Company’s previously registered products. MDR is a replacement of the existing European Medical Devices Directive regulatory framework, and manufacturers of currently marketed medical devices were required to comply with EU MDR beginning in May 2021. The Company considers the adoption of EU MDR to be a significant one-time regulatory change and is not indicative of on-going operations. The Company has excluded only external third-party regulatory and consulting costs from its MedTech operating segments' measures of profit and loss used for making operating decisions and assessing performance which is expected to be completed during 2024.

 

4

The tax impact related to special item adjustments reflects the current and deferred income taxes associated with the above pre-tax special items in arriving at adjusted earnings.

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measure
 
Adjusted Operational Sales Growth
SECOND QUARTER 2023 ACTUAL vs. 2022 ACTUAL
Segments
 
Consumer Health Pharmaceutical MedTech Total
 
WW As Reported

5.4

%

3.1

%

12.9

%

6.3

%

U.S.

6.0

%

9.2

%

14.6

%

10.2

%

International

5.0

%

(4.0

)%

11.3

%

2.2

%

 
WW Currency

(2.3

)

(0.7

)

(1.8

)

(1.2

)

U.S.

-

 

-

 

-

 

-

 

International

(4.0

)

(1.5

)

(3.4

)

(2.5

)

 
WW Operational

7.7

%

3.8

%

14.7

%

7.5

%

U.S.

6.0

%

9.2

%

14.6

%

10.2

%

International

9.0

%

(2.5

)%

14.7

%

4.7

%

 
Abiomed

(4.8

)

(1.4

)

U.S.

(8.1

)

(2.2

)

International

(1.7

)

(0.5

)

 
All Other Acquisitions and Divestitures

0.0

 

0.1

 

0.0

 

0.1

 

U.S.

0.0

 

0.0

 

0.0

 

0.0

 

International

0.0

 

0.3

 

0.0

 

0.2

 

 
WW Adjusted Operational

7.7

%

3.9

%

9.9

%

6.2

%

U.S.

6.0

%

9.2

%

6.5

%

8.0

%

International

9.0

%

(2.2

)%

13.0

%

4.4

%

 
Note: Percentages are based on actual, non-rounded figures and may not sum
Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measure
 
Adjusted Operational Sales Growth
SIX MONTHS 2023 ACTUAL vs. 2022 ACTUAL
Segments
 
Consumer Health Pharmaceutical MedTech Total
 
WW As Reported

6.4

%

3.7

%

10.1

%

6.0

%

U.S.

8.6

%

7.6

%

15.5

%

10.0

%

International

4.7

%

(0.7

)%

5.2

%

2.0

%

 
WW Currency

(3.1

)

(1.8

)

(2.7

)

(2.2

)

U.S.

-

 

-

 

-

 

-

 

International

(5.4

)

(3.8

)

(5.1

)

(4.5

)

 
WW Operational

9.5

%

5.5

%

12.8

%

8.2

%

U.S.

8.6

%

7.6

%

15.5

%

10.0

%

International

10.1

%

3.1

%

10.3

%

6.5

%

 
Abiomed

(4.7

)

(1.4

)

U.S.

(8.2

)

(2.3

)

International

(1.6

)

(0.5

)

 
All Other Acquisitions and Divestitures

0.0

 

0.1

 

0.0

 

0.1

 

U.S.

0.0

 

0.0

 

0.0

 

0.0

 

International

0.0

 

0.3

 

0.0

 

0.2

 

 
WW Adjusted Operational

9.5

%

5.6

%

8.1

%

6.9

%

U.S.

8.6

%

7.6

%

7.3

%

7.7

%

International

10.1

%

3.4

%

8.7

%

6.2

%

 
Note: Percentages are based on actual, non-rounded figures and may not sum

REPORTED SALES vs. PRIOR PERIOD ($MM)

REPORTED SALES vs. PRIOR PERIOD ($MM)

SECOND QUARTER SIX MONTHS

% Change

% Change

2023

2022

Reported

Operational (1)

Currency

2023

2022

Reported

Operational (1)

Currency

CONSUMER HEALTH SEGMENT (2)
OTC
US

$

712

663

7.5%

7.5%

-

$

1,457

1,333

9.3%

9.3%

-

Intl

 

947

818

15.7%

19.0%

-3.3%

 

1,844

1,609

14.6%

19.4%

-4.8%

WW

 

1,659

1,482

12.0%

13.9%

-1.9%

 

3,301

2,943

12.2%

14.8%

-2.6%

SKIN HEALTH / BEAUTY
US

 

650

629

3.4%

3.4%

-

 

1,267

1,173

8.0%

8.0%

-

Intl

 

498

497

0.3%

3.8%

-3.5%

 

991

965

2.7%

8.1%

-5.4%

WW

 

1,148

1,126

2.0%

3.5%

-1.5%

 

2,258

2,138

5.6%

8.0%

-2.4%

ORAL CARE
US

 

173

170

1.7%

1.7%

-

 

332

313

6.2%

6.2%

-

Intl

 

225

224

0.3%

3.4%

-3.1%

 

427

447

-4.7%

-0.3%

-4.4%

WW

 

398

394

0.9%

2.7%

-1.8%

 

759

760

-0.2%

2.4%

-2.6%

BABY CARE
US

 

99

88

12.5%

12.5%

-

 

195

173

12.7%

12.7%

-

Intl

 

261

287

-9.1%

-4.0%

-5.1%

 

524

557

-6.0%

0.1%

-6.1%

WW

 

360

375

-4.0%

-0.2%

-3.8%

 

719

730

-1.6%

3.1%

-4.7%

WOMEN'S HEALTH
US

 

4

3

-2.1%

-2.1%

-

 

7

7

-0.1%

-0.1%

-

Intl

 

235

228

3.5%

10.2%

-6.7%

 

449

452

-0.7%

7.2%

-7.9%

WW

 

238

230

3.4%

10.0%

-6.6%

 

455

458

-0.6%

7.1%

-7.7%

WOUND CARE / OTHER
US

 

149

133

12.3%

12.3%

-

 

264

245

7.9%

7.9%

-

Intl

 

58

65

-10.3%

-4.6%

-5.7%

 

107

117

-8.4%

-1.5%

-6.9%

WW

 

207

197

4.9%

6.8%

-1.9%

 

371

361

2.6%

4.9%

-2.3%

 
TOTAL CONSUMER HEALTH
US

 

1,787

1,687

6.0%

6.0%

-

 

3,522

3,244

8.6%

8.6%

-

Intl

 

2,224

2,118

5.0%

9.0%

-4.0%

 

4,341

4,147

4.7%

10.1%

-5.4%

WW

$

4,011

3,805

5.4%

7.7%

-2.3%

$

7,863

7,391

6.4%

9.5%

-3.1%

 
 
See footnotes at end of schedule
 
 
 

REPORTED SALES vs. PRIOR PERIOD ($MM)

REPORTED SALES vs. PRIOR PERIOD ($MM)

SECOND QUARTER

SIX MONTHS

% Change

% Change

PHARMACEUTICAL SEGMENT (2,3)

2023

2022

Reported

Operational (1)

Currency

2023

2022

Reported

Operational (1)

Currency

 
IMMUNOLOGY
US

$

2,865

2,853

0.4%

0.4%

-

$

5,313

5,354

-0.8%

-0.8%

-

Intl

 

1,631

1,559

4.7%

6.6%

-1.9%

 

3,295

3,176

3.8%

8.2%

-4.4%

WW

 

4,496

4,411

1.9%

2.6%

-0.7%

 

8,608

8,530

0.9%

2.6%

-1.7%

REMICADE
US

 

277

391

-29.3%

-29.3%

-

 

553

749

-26.2%

-26.2%

-

US Exports (4)

 

33

44

-24.9%

-24.9%

-

 

74

124

-40.3%

-40.3%

-

Intl

 

152

212

-28.2%

-25.2%

-3.0%

 

322

437

-26.2%

-22.5%

-3.7%

WW

 

462

647

-28.6%

-27.6%

-1.0%

 

949

1,310

-27.5%

-26.3%

-1.2%

SIMPONI / SIMPONI ARIA
US

 

285

301

-5.1%

-5.1%

-

 

556

588

-5.4%

-5.4%

-

Intl

 

244

266

-8.2%

-4.3%

-3.9%

 

510

549

-7.1%

-1.1%

-6.0%

WW

 

529

566

-6.6%

-4.7%

-1.9%

 

1,066

1,137

-6.2%

-3.3%

-2.9%

STELARA
US

 

1,817

1,731

4.9%

4.9%

-

 

3,268

3,110

5.1%

5.1%

-

Intl

 

981

868

13.0%

14.1%

-1.1%

 

1,974

1,777

11.1%

15.2%

-4.1%

WW

 

2,797

2,599

7.6%

8.0%

-0.4%

 

5,241

4,887

7.2%

8.7%

-1.5%

TREMFYA
US

 

450

382

17.8%

17.8%

-

 

856

773

10.7%

10.7%

-

Intl

 

255

214

19.4%

21.0%

-1.6%

 

489

413

18.4%

22.8%

-4.4%

WW

 

706

597

18.3%

18.9%

-0.6%

 

1,346

1,187

13.4%

15.0%

-1.6%

OTHER IMMUNOLOGY
US

 

4

3

17.8%

17.8%

-

 

7

9

-30.2%

-30.2%

-

Intl

 

0

0

-

-

-

 

0

0

-

-

-

WW

 

4

3

17.8%

17.8%

-

 

7

9

-30.2%

-30.2%

-

INFECTIOUS DISEASES
US

 

395

415

-4.9%

-4.9%

-

 

787

876

-10.2%

-10.2%

-

Intl

 

727

901

-19.4%

-22.0%

2.6%

 

1,920

1,737

10.5%

12.3%

-1.8%

WW

 

1,121

1,316

-14.8%

-16.6%

1.8%

 

2,707

2,613

3.6%

4.7%

-1.1%

COVID-19 VACCINE
US

 

-

45

* *

-

 

-

120

* *

-

Intl

 

285

499

-43.0%

-47.4%

4.4%

 

1,032

881

17.1%

18.4%

-1.3%

WW

 

285

544

-47.7%

-51.8%

4.1%

 

1,032

1,001

3.0%

4.2%

-1.2%

EDURANT / rilpivirine
US

 

8

9

-9.0%

-9.0%

-

 

17

18

-5.3%

-5.3%

-

Intl

 

258

215

19.9%

17.3%

2.6%

 

529

454

16.4%

18.0%

-1.6%

WW

 

266

225

18.6%

16.2%

2.4%

 

546

473

15.6%

17.1%

-1.5%

PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA
US

 

382

355

7.6%

7.6%

-

 

760

724

5.0%

5.0%

-

Intl

 

109

110

-0.2%

-1.0%

0.8%

 

208

242

-13.9%

-12.1%

-1.8%

WW

 

491

464

5.8%

5.6%

0.2%

 

968

965

0.3%

0.7%

-0.4%

OTHER INFECTIOUS DISEASES
US

 

5

6

-27.2%

-27.2%

-

 

10

14

-30.6%

-30.6%

-

Intl

 

74

77

-3.5%

3.6%

-7.1%

 

151

160

-5.6%

-1.2%

-4.4%

WW

 

79

83

-5.2%

1.3%

-6.5%

 

161

174

-7.6%

-3.6%

-4.0%

 
 
 
 

REPORTED SALES vs. PRIOR PERIOD ($MM)

REPORTED SALES vs. PRIOR PERIOD ($MM)

SECOND QUARTER

SIX MONTHS

% Change

% Change

2023

2022

Reported

Operational (1)

Currency

2023

2022

Reported

Operational (1)

Currency

NEUROSCIENCE
US

 

1,029

896

14.9%

14.9%

-

 

2,007

1,739

15.4%

15.4%

-

Intl

 

764

837

-8.8%

-4.6%

-4.2%

 

1,590

1,735

-8.4%

-3.8%

-4.6%

WW

 

1,793

1,734

3.5%

5.5%

-2.0%

 

3,597

3,475

3.5%

5.8%

-2.3%

CONCERTA / Methylphenidate
US

 

64

38

68.2%

68.2%

-

 

134

73

84.0%

84.0%

-

Intl

 

143

123

16.3%

21.3%

-5.0%

 

279

245

13.9%

20.7%

-6.8%

WW

 

208

161

28.6%

32.4%

-3.8%

 

414

318

30.0%

35.3%

-5.3%

INVEGA SUSTENNA / XEPLION /
INVEGA TRINZA / TREVICTA
US

 

721

691

4.3%

4.3%

-

 

1,434

1,352

6.0%

6.0%

-

Intl

 

310

362

-14.4%

-12.6%

-1.8%

 

641

749

-14.5%

-10.7%

-3.8%

WW

 

1,031

1,054

-2.1%

-1.5%

-0.6%

 

2,075

2,102

-1.3%

0.1%

-1.4%

SPRAVATO
US

 

144

74

93.2%

93.2%

-

 

255

135

88.3%

88.3%

-

Intl

 

25

11

* * *

 

45

20

* * *
WW

 

169

85

98.2%

98.5%

-0.3%

 

300

155

93.1%

93.8%

-0.7%

OTHER NEUROSCIENCE
US

 

100

93

9.3%

9.3%

-

 

184

179

3.1%

3.1%

-

Intl

 

286

341

-16.4%

-9.9%

-6.5%

 

625

721

-13.4%

-8.7%

-4.7%

WW

 

386

433

-10.9%

-5.8%

-5.1%

 

809

900

-10.1%

-6.4%

-3.7%

ONCOLOGY
US

 

2,069

1,679

23.2%

23.2%

-

 

3,958

3,261

21.4%

21.4%

-

Intl

 

2,329

2,362

-1.4%

0.1%

-1.5%

 

4,552

4,731

-3.8%

0.0%

-3.8%

WW

 

4,398

4,042

8.8%

9.7%

-0.9%

 

8,510

7,992

6.5%

8.8%

-2.3%

CARVYKTI
US

 

114

24

* *

-

 

184

24

* *

-

Intl

 

3

-

* * *

 

5

-

* * *
WW

 

117

24

* * *

 

189

24

* * *
DARZALEX
US

 

1,322

1,021

29.5%

29.5%

-

 

2,513

1,974

27.3%

27.3%

-

Intl

 

1,110

965

15.0%

17.0%

-2.0%

 

2,182

1,868

16.8%

21.5%

-4.7%

WW

 

2,431

1,986

22.4%

23.4%

-1.0%

 

4,695

3,842

22.2%

24.5%

-2.3%

ERLEADA
US

 

241

233

3.6%

3.6%

-

 

490

439

11.8%

11.8%

-

Intl

 

326

218

49.7%

51.7%

-2.0%

 

619

412

50.3%

55.9%

-5.6%

WW

 

567

450

25.9%

26.9%

-1.0%

 

1,109

850

30.4%

33.2%

-2.8%

IMBRUVICA
US

 

262

349

-24.9%

-24.9%

-

 

532

719

-26.0%

-26.0%

-

Intl

 

579

620

-6.7%

-5.7%

-1.0%

 

1,136

1,288

-11.8%

-8.8%

-3.0%

WW

 

841

970

-13.2%

-12.6%

-0.6%

 

1,668

2,008

-16.9%

-15.0%

-1.9%

ZYTIGA / abiraterone acetate
US

 

9

19

-55.2%

-55.2%

-

 

25

38

-34.7%

-34.7%

-

Intl

 

218

486

-55.1%

-53.8%

-1.3%

 

447

1,006

-55.6%

-53.0%

-2.6%

WW

 

227

505

-55.1%

-53.8%

-1.3%

 

472

1,044

-54.8%

-52.3%

-2.5%

OTHER ONCOLOGY
US

 

122

33

* *

-

 

214

67

* *

-

Intl

 

92

72

27.8%

29.4%

-1.6%

 

162

156

3.6%

7.1%

-3.5%

WW

 

214

106

* * *

 

376

224

68.0%

70.4%

-2.4%

 
 
 
 

REPORTED SALES vs. PRIOR PERIOD ($MM)

REPORTED SALES vs. PRIOR PERIOD ($MM)

SECOND QUARTER SIX MONTHS

% Change

% Change

2023

2022

Reported

Operational (1)

Currency

2023

2022

Reported

Operational (1)

Currency

PULMONARY HYPERTENSION
US

 

684

560

22.0%

22.0%

-

 

1,284

1,132

13.4%

13.4%

-

Intl

 

289

284

2.0%

5.7%

-3.7%

 

561

563

-0.4%

5.5%

-5.9%

WW

 

972

843

15.3%

16.5%

-1.2%

 

1,844

1,695

8.8%

10.8%

-2.0%

OPSUMIT
US

 

328

265

23.7%

23.7%

-

 

601

538

11.6%

11.6%

-

Intl

 

179

173

3.4%

6.0%

-2.6%

 

346

343

0.9%

6.1%

-5.2%

WW

 

507

438

15.7%

16.7%

-1.0%

 

947

881

7.5%

9.5%

-2.0%

UPTRAVI
US

 

338

272

24.2%

24.2%

-

 

642

541

18.7%

18.7%

-

Intl

 

61

56

10.0%

14.1%

-4.1%

 

119

112

6.6%

11.7%

-5.1%

WW

 

399

328

21.8%

22.5%

-0.7%

 

761

653

16.6%

17.5%

-0.9%

OTHER PULMONARY HYPERTENSION
US

 

18

23

-23.8%

-23.8%

-

 

41

53

-23.0%

-23.0%

-

Intl

 

48

55

-10.9%

-3.7%

-7.2%

 

95

108

-11.7%

-2.8%

-8.9%

WW

 

66

78

-14.7%

-9.7%

-5.0%

 

136

161

-15.5%

-9.5%

-6.0%

CARDIOVASCULAR / METABOLISM / OTHER
US

 

776

757

2.6%

2.6%

-

 

1,491

1,429

4.3%

4.3%

-

Intl

 

174

215

-19.0%

-18.3%

-0.7%

 

386

453

-14.7%

-12.0%

-2.7%

WW

 

950

972

-2.2%

-2.0%

-0.2%

 

1,877

1,882

-0.3%

0.4%

-0.7%

XARELTO
US

 

637

609

4.7%

4.7%

-

 

1,215

1,117

8.8%

8.8%

-

Intl

 

-

-

-

-

-

 

-

-

-

-

-

WW

 

637

609

4.7%

4.7%

-

 

1,215

1,117

8.8%

8.8%

-

OTHER
US

 

138

148

-6.3%

-6.3%

-

 

275

312

-11.8%

-11.8%

-

Intl

 

174

215

-19.0%

-18.3%

-0.7%

 

386

453

-14.7%

-12.0%

-2.7%

WW

 

313

363

-13.8%

-13.4%

-0.4%

 

662

765

-13.5%

-11.9%

-1.6%

 
TOTAL PHARMACEUTICAL
US

 

7,818

7,159

9.2%

9.2%

-

 

14,841

13,791

7.6%

7.6%

-

Intl

 

5,913

6,158

-4.0%

-2.5%

-1.5%

 

12,303

12,395

-0.7%

3.1%

-3.8%

WW

$

13,731

13,317

3.1%

3.8%

-0.7%

$

27,144

26,186

3.7%

5.5%

-1.8%

 
 
See footnotes at end of schedule
 
 

REPORTED SALES vs. PRIOR PERIOD ($MM)

REPORTED SALES vs. PRIOR PERIOD ($MM)

SECOND QUARTER SIX MONTHS

% Change

% Change

MEDTECH SEGMENT (2,3)

2023

2022

Reported

Operational (1)

Currency

2023

2022

Reported

Operational (1)

Currency

 
INTERVENTIONAL SOLUTIONS
US

$

908

525

73.1%

73.1%

-

$

1,771

1,019

73.8%

73.8%

-

Intl

 

712

525

35.7%

40.7%

-5.0%

 

1,352

1,123

20.5%

27.0%

-6.5%

WW

 

1,620

1,049

54.4%

56.9%

-2.5%

 

3,123

2,141

45.8%

49.3%

-3.5%

ELECTROPHYSIOLOGY
US

 

609

499

22.0%

22.0%

-

 

1,180

969

21.7%

21.7%

-

Intl

 

587

469

25.1%

30.0%

-4.9%

 

1,109

1,001

10.8%

17.3%

-6.5%

WW

 

1,196

968

23.5%

25.9%

-2.4%

 

2,288

1,970

16.2%

19.5%

-3.3%

ABIOMED
US

 

272

-

* *

-

 

536

-

* *

-

Intl

 

59

-

* * *

 

119

-

* * *
WW

 

331

-

* * *

 

655

-

* * *
OTHER INTERVENTIONAL SOLUTIONS
US

 

27

26

4.5%

4.5%

-

 

55

50

10.8%

10.8%

-

Intl

 

67

56

20.0%

25.3%

-5.3%

 

125

121

2.8%

8.9%

-6.1%

WW

 

93

81

15.1%

18.8%

-3.7%

 

180

171

5.1%

9.5%

-4.4%

ORTHOPAEDICS
US

 

1,388

1,338

3.7%

3.7%

-

 

2,751

2,627

4.7%

4.7%

-

Intl

 

878

820

7.0%

9.0%

-2.0%

 

1,759

1,719

2.3%

6.4%

-4.1%

WW

 

2,265

2,157

5.0%

5.7%

-0.7%

 

4,510

4,345

3.8%

5.4%

-1.6%

HIPS
US

 

250

240

4.1%

4.1%

-

 

491

465

5.6%

5.6%

-

Intl

 

147

148

-0.8%

1.2%

-2.0%

 

296

312

-5.1%

-1.3%

-3.8%

WW

 

397

388

2.2%

3.0%

-0.8%

 

787

777

1.3%

2.8%

-1.5%

KNEES
US

 

221

216

2.4%

2.4%

-

 

447

417

7.2%

7.2%

-

Intl

 

142

133

6.3%

8.0%

-1.7%

 

284

271

4.8%

8.8%

-4.0%

WW

 

363

349

3.9%

4.5%

-0.6%

 

731

688

6.3%

7.9%

-1.6%

TRAUMA
US

 

483

464

4.3%

4.3%

-

 

974

939

3.7%

3.7%

-

Intl

 

255

232

9.9%

10.9%

-1.0%

 

522

505

3.2%

7.0%

-3.8%

WW

 

739

696

6.1%

6.5%

-0.4%

 

1,496

1,444

3.6%

4.9%

-1.3%

SPINE, SPORTS & OTHER
US

 

433

418

3.5%

3.5%

-

 

839

805

4.1%

4.1%

-

Intl

 

334

306

9.0%

11.6%

-2.6%

 

657

630

4.2%

8.7%

-4.5%

WW

 

766

724

5.8%

7.0%

-1.2%

 

1,495

1,436

4.2%

6.1%

-1.9%

 
 
 
 

REPORTED SALES vs. PRIOR PERIOD ($MM)

REPORTED SALES vs. PRIOR PERIOD ($MM)

SECOND QUARTER SIX MONTHS

% Change

% Change

2023

2022

Reported

Operational (1)

Currency

2023

2022

Reported

Operational (1)

Currency

SURGERY
US

 

1,015

992

2.2%

2.2%

-

 

1,990

1,913

4.0%

4.0%

-

Intl

 

1,580

1,458

8.4%

12.6%

-4.2%

 

3,039

2,971

2.3%

7.7%

-5.4%

WW

 

2,594

2,450

5.9%

8.4%

-2.5%

 

5,028

4,884

3.0%

6.3%

-3.3%

ADVANCED
US

 

466

454

2.7%

2.7%

-

 

910

871

4.5%

4.5%

-

Intl

 

757

702

7.8%

12.1%

-4.3%

 

1,430

1,431

0.0%

5.3%

-5.3%

WW

 

1,222

1,156

5.8%

8.4%

-2.6%

 

2,340

2,302

1.7%

5.0%

-3.3%

GENERAL
US

 

548

538

1.9%

1.9%

-

 

1,079

1,042

3.6%

3.6%

-

Intl

 

823

756

8.9%

13.1%

-4.2%

 

1,608

1,540

4.5%

10.0%

-5.5%

WW

 

1,372

1,294

6.0%

8.4%

-2.4%

 

2,688

2,582

4.1%

7.4%

-3.3%

VISION
US

 

529

496

6.6%

6.6%

-

 

1,087

1,017

6.9%

6.9%

-

Intl

 

778

745

4.6%

7.1%

-2.5%

 

1,521

1,481

2.7%

7.5%

-4.8%

WW

 

1,308

1,241

5.4%

6.9%

-1.5%

 

2,608

2,498

4.4%

7.2%

-2.8%

CONTACT LENSES / OTHER
US

 

409

374

9.1%

9.1%

-

 

853

774

10.1%

10.1%

-

Intl

 

530

519

2.2%

4.8%

-2.6%

 

1,039

1,030

0.9%

6.3%

-5.4%

WW

 

939

894

5.1%

6.6%

-1.5%

 

1,892

1,804

4.9%

8.0%

-3.1%

SURGICAL
US

 

120

122

-1.1%

-1.1%

-

 

234

243

-3.6%

-3.6%

-

Intl

 

249

225

10.1%

12.3%

-2.2%

 

482

451

6.7%

10.2%

-3.5%

WW

 

369

347

6.2%

7.6%

-1.4%

 

716

694

3.1%

5.4%

-2.3%

 
TOTAL MEDTECH
US

 

3,839

3,351

14.6%

14.6%

-

 

7,598

6,576

15.5%

15.5%

-

Intl

 

3,949

3,547

11.3%

14.7%

-3.4%

 

7,671

7,293

5.2%

10.3%

-5.1%

WW

$

7,788

6,898

12.9%

14.7%

-1.8%

$

15,269

13,869

10.1%

12.8%

-2.7%

 
 

Note: Columns and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely

 

* Percentage greater than 100% or not meaningful

(1) Operational growth excludes the effect of translational currency

(2) Unaudited

(3) Certain prior year amounts have been reclassified to conform to current year product disclosures

(4) Reported as U.S. sales

 

Supplemental Sales Reconciliation (Unaudited) 

(Dollars in Millions)

 

SECOND QUARTER

SIX MONTHS

Percent Change

Percent Change

2023

2022

Total

Operations

Currency

2023

2022

Total

Operations

Currency

Pharmaceutical
U.S.

$

7,818

7,159

9.2

 

%

9.2

 

-

 

$

14,841

13,791

7.6

 

%

7.6

-

 

International

 

5,913

6,158

(4.0

)

(2.5

)

(1.5

)

 

12,303

12,395

(0.7

)

3.1

(3.8

)

Worldwide

 

13,731

13,317

3.1

 

3.8

 

(0.7

)

 

27,144

26,186

3.7

 

5.5

(1.8

)

COVID-19 Vaccine
U.S.

 

-

45

* *

-

 

 

-

120

* *

-

 

International

 

285

499

(43.0

)

(47.4

)

4.4

 

 

1,032

881

17.1

 

18.4

(1.3

)

Worldwide

 

285

544

(47.7

)

(51.8

)

4.1

 

 

1,032

1,001

3.0

 

4.2

(1.2

)

Pharmaceutical excluding COVID-19 Vaccine
U.S.

 

7,818

7,114

9.9

 

9.9

 

-

 

 

14,841

13,671

8.6

 

8.6

-

 

International

 

5,628

5,659

(0.5

)

1.5

 

(2.0

)

 

11,271

11,514

(2.1

)

1.9

(4.0

)

Worldwide

 

13,446

12,773

5.3

 

6.2

 

(0.9

)

 

26,112

25,185

3.7

 

5.5

(1.8

)

Worldwide
U.S.

 

13,444

12,197

10.2

 

10.2

 

-

 

 

25,961

23,611

10.0

 

10.0

-

 

International

 

12,086

11,823

2.2

 

4.7

 

(2.5

)

 

24,315

23,835

2.0

 

6.5

(4.5

)

Worldwide

 

25,530

24,020

6.3

 

7.5

 

(1.2

)

 

50,276

47,446

6.0

 

8.2

(2.2

)

COVID-19 Vaccine
U.S.

 

-

45

* *

-

 

 

-

120

* *

-

 

International

 

285

499

(43.0

)

(47.4

)

4.4

 

 

1,032

881

17.1

 

18.4

(1.3

)

Worldwide

 

285

544

(47.7

)

(51.8

)

4.1

 

 

1,032

1,001

3.0

 

4.2

(1.2

)

Worldwide
U.S.

 

13,444

12,152

10.6

 

10.6

 

-

 

 

25,961

23,491

10.5

 

10.5

-

 

International

 

11,801

11,324

4.2

 

7.0

 

(2.8

)

 

23,283

22,954

1.4

 

6.1

(4.7

)

Worldwide excluding COVID-19 Vaccine

$

25,245

23,476

7.5

 

%

8.9

 

(1.4

)

$

49,244

46,445

6.0

 

%

8.3

(2.3

)

 
Note: Columns and rows within tables may not add due to rounding
* Percentage greater than 100% or not meaningful
 
Johnson & Johnson and Subsidiaries  
Reconciliation of Non-GAAP Financial Measures  

Q2 QTD - Income Before Tax by Segment*

Dollars in Millions

Consumer Health
Separation Costs

Consumer Health

Pharmaceutical

MedTech

Unallocated

Worldwide Total

2023

2022

2023

2022

2023

2022

2023

2022

2023

2022

2023

2022

Reported Income Before Tax by Segment   $

860

784

4,862

4,420

1,699

1,141

(377)

(237)

(282)

(268)

6,762

5,840

% to Sales

21.4%

20.6%

35.4%

33.2%

21.8%

16.5%

-1.5%

-1.0%

-1.1%

-1.1%

26.5%

24.3%

Intangible asset amortization expense  

81

100

748

736

382

259

-

-

-

-

1,211

1,095

In-process research and development  

-

-

-

-

-

-

-

-

-

-

-

-

Litigation related  

-

78

(93)

36

60

271

170

-

-

-

137

385

COVID-19 Vaccine related costs  

-

-

165

276

-

-

-

-

-

-

165

276

Loss/(gain) on securities  

-

-

38

102

(39)

7

-

-

-

-

(1)

109

Restructuring related  

-

25

145

23

-

80

-

-

-

-

145

128

Acquisition, integration and divestiture related  

-

-

-

-

38

-

-

-

-

-

38

-

Medical Device Regulation  

-

-

-

-

85

70

-

-

-

-

85

70

Consumer Health separation costs  

-

-

-

-

-

-

-

-

282

268

282

268

-

Other

-

-

-

-

-

-

-

-

-

-

-

Adjusted Income Before Tax by Segment   $

941

987

5,865

5,593

2,225

1,828

(207)

(237)

-

-

8,824

8,171

% to Sales

23.5%

25.9%

42.7%

42.0%

28.6%

26.5%

-0.8%

-1.0%

0.0%

0.0%

34.6%

34.0%

*Estimated as of 7/20/2023  
Johnson & Johnson and Subsidiaries                        
Reconciliation of Non-GAAP Financial Measures                        
Q2 YTD - Income Before Tax by Segment*
Dollars in Millions
                         
 

Consumer Health

 

Pharmaceutical

 

MedTech

 

Unallocated

 

Consumer Health
Separation Costs

 

Worldwide Total

 

2023

 

2022

 

2023

 

2022

 

2023

 

2022

 

2023

 

2022

 

2023

 

2022

 

2023

 

2022

                         
Reported Income Before Tax by Segment   $

1,636

 

1,470

 

9,306

 

8,344

 

3,144

 

2,618

 

(7,479)

 

(360)

 

(582)

 

(370)

 

6,025

 

11,702

% to Sales  

20.8%

 

19.9%

 

34.3%

 

31.9%

 

20.6%

 

18.9%

 

-14.9%

 

-0.8%

 

-1.2%

 

-0.8%

 

12.0%

 

24.7%

                         
Intangible asset amortization expense  

163

 

194

 

1,487

 

1,496

 

765

 

513

 

-

 

-

 

-

 

-

 

2,415

 

2,203

                         
In-process research and development  

-

 

-

 

-

 

610

 

49

 

-

 

-

 

-

 

-

 

-

 

49

 

610

                         
Litigation related  

-

 

78

 

(93)

 

36

 

60

 

271

 

7,070

 

-

 

-

 

-

 

7,037

 

385

                         
COVID-19 Vaccine related costs  

-

 

-

 

609

 

276

 

-

 

-

 

-

 

-

 

-

 

-

 

609

 

276

                         
Loss/(gain) on securities  

-

 

-

 

76

 

496

 

(5)

 

24

 

-

 

-

 

-

 

-

 

71

 

520

                         
Restructuring related  

-

 

39

 

275

 

9

 

-

 

152

 

-

 

-

 

-

 

-

 

275

 

200

                         
Acquisition, integration and divestiture related  

-

 

-

 

-

 

-

 

80

 

-

 

-

 

-

 

-

 

-

 

80

 

-

                         
Medical Device Regulation  

-

 

-

 

-

 

-

 

149

 

130

 

-

 

-

 

-

 

-

 

149

 

130

                         
Consumer Health separation costs  

-

 

-

 

-

 

-

 

-

 

-

 

-

 

-

 

582

 

370

 

582

 

370

                         
Other  

-

 

-

 

-

 

-

 

-

 

-

 

-

 

(7)

 

-

 

-

 

-

 

(7)

                         
Adjusted Income Before Tax by Segment   $

1,799

 

1,781

 

11,660

 

11,267

 

4,242

 

3,708

 

(409)

 

(367)

 

-

 

-

 

17,292

 

16,389

% to Sales  

22.9%

 

24.1%

 

43.0%

 

43.0%

 

27.8%

 

26.7%

 

-0.8%

 

-0.8%

 

0.0%

 

0.0%

 

34.4%

 

34.5%

                         
*Estimated as of 7/20/2023
 
Johnson & Johnson and Subsidiaries
GAAP to Non-GAAP Reconciliation
$ in Millions
 
Quarter to Date

 

Second Quarter
July 2, 2023
GAAP

Intangible asset
amortization

Litigation
related

In-process
research and
development

Restructuring
related

Acquisition,
integration and
divestiture related

(Loss)/gain
on
securities

Medical
Device
Regulation

COVID-19 Vaccine
Related
Costs

Consumer Health
separation
costs

Consumer Health
separation
tax related
costs

Tax legislation
and other
tax related

Other

Second Quarter
July 3, 2022
Non-GAAP

Cost of products sold

$

8,212

 

(1,211

)

-

 

(34

)

38

 

(14

)

-

 

-

 

-

 

6,991

 

Selling, marketing and admin expenses

 

6,665

 

(8

)

(44

)

6,613

 

Research and development expense

 

3,829

 

-

 

(44

)

(46

)

(2

)

3,737

 

Other (Income) / Expense

 

(60

)

-

 

(137

)

-

 

(38

)

1

 

(156

)

(221

)

-

 

-

 

(611

)

In-process research and development

 

-

 

-

 

-

 

Interest (Income)/Expense

 

(23

)

(1

)

(24

)

Restructuring

 

145

 

(145

)

-

 

Provision for taxes on income

 

1,618

 

194

 

29

 

-

 

37

 

12

 

(1

)

15

 

38

 

49

 

(546

)

21

 

-

 

1,466

 

Net Earnings

 

5,144

 

1,017

 

108

 

-

 

108

 

26

 

-

 

71

 

126

 

233

 

546

 

(21

)

-

 

7,358

 

 

 

Second Quarter
July 3, 2022
GAAP

Intangible asset
amortization

Litigation
related

In-process
research and
development

Restructuring
related

Acquisition,
integration and
divestiture related

(Loss)/gain
on
securities

Medical
Device
Regulation

COVID-19 Vaccine
Related
Costs

Consumer Health
separation
costs

Consumer Health
separation
tax related
costs

Tax legislation
and other
tax related

Other

Second Quarter
July 3, 2022
Non-GAAP

Cost of products sold

$

7,919

 

(1,083

)

(17

)

(25

)

(194

)

-

 

-

 

-

 

-

 

6,600

 

Selling, marketing and admin expenses

 

6,226

 

(6

)

6,220

 

Research and development expense

 

3,703

 

-

 

(39

)

(110

)

3,554

 

Other (Income) / Expense

 

273

 

(12

)

(385

)

(26

)

-

 

(109

)

28

 

(268

)

-

 

-

 

(499

)

In-process research and development

 

-

 

-

 

-

 

Restructuring

 

85

 

(85

)

-

 

Provision for taxes on income

 

1,026

 

170

 

(29

)

-

 

25

 

-

 

25

 

13

 

65

 

44

 

(2

)

(78

)

-

 

1,259

 

Net Earnings

 

4,814

 

925

 

414

 

-

 

103

 

-

 

84

 

57

 

211

 

224

 

2

 

78

 

-

 

6,912

 

 
Year to Date

 

Six Months
July 2, 2023
GAAP

Intangible asset
amortization

Litigation
related

In-process
research and
development

Restructuring
related

Acquisition,
integration and
divestiture related

(Loss)/gain
on
securities

Medical
Device
Regulation

COVID-19 Vaccine
Related
Costs

Consumer Health
separation
costs

Consumer Health
separation
tax related
costs

Tax legislation
and other
tax related

Other

Six Months
July 2, 2023
Non-GAAP

Cost of products sold

$

16,607

 

(2,411

)

-

 

(57

)

(168

)

(26

)

13,945

 

Selling, marketing and admin expenses

 

12,803

 

(15

)

(82

)

12,706

 

Research and development expense

 

7,392

 

(16

)

(78

)

(62

)

(4

)

7,232

 

Other (Income) / Expense

 

7,168

 

(4

)

(7,037

)

-

 

(64

)

(71

)

(378

)

(506

)

-

 

-

 

(892

)

In-process research and development

 

49

 

(49

)

-

 

-

 

-

 

Interest (Income)/Expense

 

(43

)

36

 

(7

)

Restructuring

 

275

 

(275

)

-

 

Provision for taxes on income

 

949

 

388

 

1,651

 

11

 

69

 

17

 

15

 

27

 

143

 

109

 

(557

)

44

 

-

 

2,866

 

Net Earnings

 

5,076

 

2,027

 

5,386

 

38

 

206

 

63

 

56

 

123

 

465

 

473

 

557

 

(44

)

-

 

14,426

 

 

 

Six Months
July 3, 2022
GAAP

Intangible asset
amortization

Litigation
related

In-process
research and
development

Restructuring
related

Acquisition,
integration and
divestiture related

(Loss)/gain
on
securities

Medical
Device
Regulation

COVID-19 Vaccine
Related
Costs

Consumer Health
separation
costs

Consumer Health
separation
tax related
costs

Tax legislation
and other
tax related

Other

Six Months
July 3, 2022
Non-GAAP

Cost of products sold

$

15,517

 

(2,191

)

(33

)

(47

)

(194

)

13,052

 

Selling, marketing and admin expenses

 

12,164

 

(12

)

12,152

 

Research and development expense

 

7,165

 

-

 

(71

)

(110

)

6,984

 

Other (Income) / Expense

 

171

 

(12

)

(385

)

(12

)

-

 

(520

)

28

 

(370

)

-

 

7

 

(1,093

)

In-process research and development

 

610

 

(610

)

-

 

Restructuring

 

155

 

(155

)

-

 

Provision for taxes on income

 

1,739

 

338

 

(82

)

138

 

37

 

-

 

121

 

24

 

65

 

67

 

(98

)

1

 

(2

)

2,348

 

Net Earnings

 

9,963

 

1,865

 

467

 

472

 

163

 

-

 

399

 

106

 

211

 

303

 

98

 

(1

)

(5

)

14,041

 

 

Contacts

Press:

Tesia Williams
media-relations@its.jnj.com

Investors:

Jessica Moore
investor-relations@its.jnj.com

Contacts

Press:

Tesia Williams
media-relations@its.jnj.com

Investors:

Jessica Moore
investor-relations@its.jnj.com